---
document_datetime: 2023-10-31 11:06:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/carmustine-medac-previously-carmustine-obvius-epar-all-authorised-presentations_en.pdf
document_name: carmustine-medac-previously-carmustine-obvius-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6636015
conversion_datetime: 2025-12-25 10:00:26.247956
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                          | Route of Administration   | Immediate Packaging                        | Content (concentration)      | Pack size       |
|------------------|-------------------|------------|----------------------------------------------|---------------------------|--------------------------------------------|------------------------------|-----------------|
| EU/1/18/1278/001 | Carmustine medac  | 100 mg     | Powder and solvent for solution for infusion | Intravenous use           | Powder: vial (glass) Solvent: vial (glass) | Powder: 100 mg Solvent: 3 ml | 1 vial + 1 vial |